my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
14-09-2009: Inserm Transfert and Innate Pharma announce the execution of an agreement facilitating the development of antibodies in cancer, inflammation and auto-immunity. This partnership of a new kind will enable Innate Pharma to be informed of the discovery of promising antibody targets at an early stage, and in turn to collaborate with academic scientists to develop drug candidates directed to such targets. On Inserm’s side, it will accelerate the identification and validation of targets with market potential.
This agreement includes three main stages:
- Inserm Transfert will make available to Innate Pharma, for preliminary evaluation, information on early-stage antibody targets (within the scope of the agreement) discovered by Inserm academic laboratories;
- For targets selected by Innate Pharma following this preliminary evaluation, Inserm and Innate Pharma will implement a collaborative research program to advance and mature the project towards the development of a drug candidate. The partners will enter into an option agreement for a potential license of the target by Innate
Pharma;
- At the end of the collaborative research program, Innate Pharma may exercise its option and enter into a licensing agreement.
Data generated during the collaboration for targets not retained by Innate Pharma will be the property of Inserm.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Mount Sinai researchers find potential therapeutic target across a range of cancer types
Researchers from Mount Sinai School of Medicine, in collaboration with investigators of the National Institute of Health and Medical Research (INSERM) of France led by Nicolae Ghinea, PhD, have found a common link among several malignant tumor types in all grades of cancer. This breakthroug ... more
Submitted by the end of 2008, the project REBORNE for 'Regenerating Bone defects using New biomedical Engineering approaches' has been accepted by the European Commission in the thematic area Health of the 7th Framework Program. Coordinated by Inserm supported by Alcimed for the project man ... more
Inserm Transfert and Innate Pharma announce the execution of an agreement facilitating the development of antibodies in cancer, inflammation and auto-immunity. This partnership of a new kind will enable Innate Pharma to be informed of the discovery of promising antibody targets at an early ... more
Sebia partners with Inserm Transfert to develop a unique diagnostic test for haemoglobin diseases
Sebia announced that it has entered into partnership with Inserm (the French National Institute of Health and Medical Research) and Inserm Transfert, its private subsidiary responsible for marketing the outcomes of its scientific research, to develop and commercialize a unique biological te ... more
TcLand Expression signs a licensing agreement with Inserm Transfert
TcLand Expression SA announced the signature of a licensing agreement with Inserm Transfert. The terms of the agreement include the grant of worldwide, exclusive licenses to TcLand Expression for two different patents covering gene expression signatures which can predict responsiveness to r ... more
Inserm Transfert and Innate Pharma announce the execution of an agreement facilitating the development of antibodies in cancer, inflammation and auto-immunity. This partnership of a new kind will enable Innate Pharma to be informed of the discovery of promising antibody targets at an early ... more
Bristol-Myers Squibb Company and Innate Pharma S.A. announced a global agreement for the development and commercialization of IPH2102, a novel antibody in Phase I development for the treatment of cancer.Under the terms of the agreement, Innate Pharma will grant to Bristol-Myers Squibb exclu ... more
Innate Pharma announced that it has started patient inclusion in a new multicenter Phase II clinical trial with IPH 2101, an anti-KIR monoclonal antibody potentiating the anti-tumor activity of NK cells. In this trial, IPH 2101 is tested as a single agent in patients with smoldering myelom ... more
Innate Pharma announced that Celgene Corporationhas agreed to collaborate with Innate Pharma to evaluate the potential clinical synergy of the combination treatment regimen of lenalidomide (REVLIMID®) plus IPH 2101 in patients with multiple myeloma (“MMy”) who have failed first-line therap ... more
Innate Pharma S.A. is a clinical-stage biopharmaceutical company developing first-in-class immunotherapy drugs for cancer and other severe diseases. The company was incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006. The company has significant expertise in identifying new ta ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
